Skip to main content
. 2024 Oct 9;11:1460372. doi: 10.3389/fmed.2024.1460372

Figure 2.

Figure 2

The sustained virologic response (SVR) to DAA in patients during 24 weeks of follow-up. SOF, Sofosbuvir; LDV, Ledipasvir; DCV, Daclatasvir.